Literature DB >> 9356625

MR imaging of the breast in patients with occult primary breast carcinoma.

E A Morris1, L H Schwartz, D D Dershaw, K J van Zee, A F Abramson, L Liberman.   

Abstract

PURPOSE: To evaluate the utility of contrast material-enhanced magnetic resonance (MR) imaging of the breast for localization of the site of primary breast carcinoma in patients with isolated ipsilateral axillary metastasis, without other focal findings at physical examination or mammography.
MATERIALS AND METHODS: Twelve women with biopsy-proved metastatic adenocarcinoma to axillary lymph nodes and occult primary tumor underwent MR imaging at 1.5 T with a three-dimensional spoiled gradient-echo pulse sequence before and after administration of gadopentetate dimeglumine. Enhancing areas were correlated with histopathologic findings at mastectomy (n = 8) or breast-conserving treatment (n = 4).
RESULTS: In nine (75%) of the 12 patients, enhancement was seen on MR images that represented the site of the primary tumor at surgery. Eight had focal masses, and one had an area of regional enhancement. Two patients had negative MR findings, and no tumor was found at mastectomy. One patient with regional enhancement on MR images had no corresponding tumor at surgery.
CONCLUSION: Breast MR imaging enables identification of the site of primary tumor in most patients suspected of having occult primary breast cancer, and MR findings can influence surgical treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9356625     DOI: 10.1148/radiology.205.2.9356625

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  16 in total

1.  Low-field versus high-field MRI in diagnosing breast disorders.

Authors:  Eija Pääkkö; Heli Reinikainen; Eija-Leena Lindholm; Tarja Rissanen
Journal:  Eur Radiol       Date:  2005-02-12       Impact factor: 5.315

Review 2.  Advances in breast imaging: magnetic resonance imaging.

Authors:  Lia Bartella; Elizabeth A Morris
Journal:  Curr Oncol Rep       Date:  2006-01       Impact factor: 5.075

Review 3.  Geographic and temporal trends in the management of occult primary breast cancer: a systematic review and meta-analysis.

Authors:  Oluwadamilola M Fayanju; Carolyn R T Stoll; Susan Fowler; Graham A Colditz; Donna B Jeffe; Julie A Margenthaler
Journal:  Ann Surg Oncol       Date:  2013-08-22       Impact factor: 5.344

Review 4.  Patterns of enhancement on breast MR images: interpretation and imaging pitfalls.

Authors:  Katarzyna J Macura; Ronald Ouwerkerk; Michael A Jacobs; David A Bluemke
Journal:  Radiographics       Date:  2006 Nov-Dec       Impact factor: 5.333

5.  Development of a Bayesian classifier for breast cancer risk stratification: a feasibility study.

Authors:  Alexander Stojadinovic; Christina Eberhardt; Leonard Henry; John Eberhardt; Eric A Elster; George E Peoples; Aviram Nissan; Craig D Shriver
Journal:  Eplasty       Date:  2010-03-29

6.  Breast MR imaging in a patient with unilateral axillary lymphadenopathy and unknown primary malignancy.

Authors:  Katrien Schelfout; E Kersschot; M Van Goethem; L Thienpont; J Van den Haute; A Roelstraete; A De Schepper
Journal:  Eur Radiol       Date:  2002-11-19       Impact factor: 5.315

7.  The role of sonography in patients with breast cancer presenting as an axillary mass.

Authors:  Sun Young Park; Eun-Kyung Kim; Ki Keun Oh; Kyong Sik Lee; Byeong-Woo Park
Journal:  Korean J Radiol       Date:  2002 Jul-Sep       Impact factor: 3.500

Review 8.  Occult breast cancer and axillary mass.

Authors:  K L Brill; D R Brenin
Journal:  Curr Treat Options Oncol       Date:  2001-04

9.  Breast MRI for evaluating patients with metastatic axillary lymph node and initially negative mammography and sonography.

Authors:  Eun Young Ko; Boo-Kyung Han; Jung Hee Shin; Seok Seon Kang
Journal:  Korean J Radiol       Date:  2007 Sep-Oct       Impact factor: 3.500

10.  Breast imaging in the new era.

Authors:  K Planche; S Vinnicombe
Journal:  Cancer Imaging       Date:  2004-01-12       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.